Rasna Therapeutics Inc logo

RASP - Rasna Therapeutics Inc Share Price

$0.077 0.0  0.0%

Last Trade - 27/10/20

Micro Cap
Market Cap £4.10m
Enterprise Value £4.44m
Revenue £n/a
Position in Universe 5851st / 6406
Unlock RASP Revenue
Relative Strength (%)
1m +4.29%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -76.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Sep 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 June 2020, RasnaTherapeutics Inc revenues was not reported. Net lossincreased from $876K to $3.1M. Higher net loss reflectsInterest on convertible notes payable increase of 45% to$30K (expense), Consultancy fees increase of 10% to $60K(expense). Basic Earnings per Share excluding ExtraordinaryItems decreased from -$0.01 to -$0.04.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


RASP Revenue Unlock RASP Revenue

Net Income

RASP Net Income Unlock RASP Revenue

Normalised EPS

RASP Normalised EPS Unlock RASP Revenue

PE Ratio Range

RASP PE Ratio Range Unlock RASP Revenue

Dividend Yield Range

RASP Dividend Yield Range Unlock RASP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RASP EPS Forecasts Unlock RASP Revenue
Profile Summary

Rasna Therapeutics, Inc., formerly Active With Me Inc., is a clinical-stage biotechnology company. The Company is focused on the development of disease-modifying drugs candidates for leukemia and lymphoma. The Company is targeting nucleophosmin (NPM1)-mutated acute myeloid leukemi (AML) through direct and indirect disease-modifying approaches. AML includes acute and chronic. It is also exploring inhibition of lysine specific demethylase-1 (LSD1), an enzyme involved in epigenetic control, as approach against AML. The Company’s product candidate includes RASP-101, RASP-201 and RASP-301. RASP-101 is an anticancer therapeutic for treating NPM1 mutated acute myeloid leukemia (AML). Formulation of RASP-101 is being developed to conduct multi-center clinical trials in NPM1 mutated AML patients.

Last Annual September 30th, 2019
Last Interim June 30th, 2020
Incorporated December 6, 2012
Public Since March 28, 2014
No. of Shareholders: 60
No. of Employees: n/a
Sector Healthcare
Industry Pharmaceuticals
Exchange Pink Sheets on Nasdaq
Shares in Issue 68,908,003
Free Float (0.0%)
Eligible for
RASP Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for RASP
Upcoming Events for RASP
Frequently Asked Questions for Rasna Therapeutics Inc
What is the Rasna Therapeutics Inc share price?

As of 27/10/20, shares in Rasna Therapeutics Inc are trading at $0.077, giving the company a market capitalisation of £4.10m. This share price information is delayed by 15 minutes.

How has the Rasna Therapeutics Inc share price performed this year?

Shares in Rasna Therapeutics Inc are currently trading at $0.077 and the price has moved by -48.67% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Rasna Therapeutics Inc price has moved by -50.31% over the past year.

What are the analyst and broker recommendations for Rasna Therapeutics Inc?

There are no analysts currently covering Rasna Therapeutics Inc.

When will Rasna Therapeutics Inc next release its financial results?

Rasna Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Rasna Therapeutics Inc dividend yield?

Rasna Therapeutics Inc does not currently pay a dividend.

Does Rasna Therapeutics Inc pay a dividend?

Rasna Therapeutics Inc does not currently pay a dividend.

When does Rasna Therapeutics Inc next pay dividends?

Rasna Therapeutics Inc does not currently pay a dividend.

How do I buy Rasna Therapeutics Inc shares?

To buy shares in Rasna Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Rasna Therapeutics Inc?

Shares in Rasna Therapeutics Inc are currently trading at $0.077, giving the company a market capitalisation of £4.10m.

Where are Rasna Therapeutics Inc shares listed? Where are Rasna Therapeutics Inc shares listed?

Here are the trading details for Rasna Therapeutics Inc:

Country of listing: United States
Exchange: PNK
Ticker Symbol: RASP
What kind of share is Rasna Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Rasna Therapeutics Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Rasna Therapeutics Inc share price forecast 2020?

We were not able to load any forecast data for Rasna Therapeutics Inc.

How can I tell whether the Rasna Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rasna Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 0.119k%. At the current price of $0.077, shares in Rasna Therapeutics Inc are trading at -94.47% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Rasna Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Rasna Therapeutics Inc.

Who are the key directors of Rasna Therapeutics Inc?

Rasna Therapeutics Inc's management team is headed by:

John Brancaccio - IND
Keeren Shah - FID
Who are the major shareholders of Rasna Therapeutics Inc?

Here are the top five shareholders of Rasna Therapeutics Inc based on the size of their shareholding:

Panetta Partners, Ltd. Corporation
Percentage owned: 12.32% (8.49m shares)
Independent Financial Partners Investment Advisor
Percentage owned: % (n/a shares)
Similar to RASP
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.